Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05263505 · ClinicalTrials.gov registry record · Phase 2
Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05263505 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 2 participants.
The verdict
NCT05263505, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence of 1 in 60,000. There are currently no FDA-approved medications for the treatment of mucous membrane pemphigoid, highlighting a clear unmet need. At present, moderate to severe disease requires off-label use of potent immunosuppressive agents, such as oral anti-proliferatives (methotrexate, azathioprine, and mycophenolate), rituximab (RTX) or cyclophosphamide (CyC). Recently, Janus kinase (JAK) inhibition with baricitinib or tofacitinib been reported to be successful in one case of ocular MMP. This is a randomized, single-masked, two-arm study of baricitinib vs anti-proliferatives for ocular MMP.
Interventions
- DRUG Methotrexate
- DRUG Azathioprine
- DRUG Mycophenolate
- DRUG Baricitinib 2 MG [Olumiant]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-02-21 |
| Est. Completion | 2023-09-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05263505
The ClinicalTrials.gov registry entry for NCT05263505 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Methotrexate is the first listed.
NCT05263505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05263505 about?
NCT05263505 is a clinical study titled "Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid". Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can lead to vision loss and permanent disability. It is a rare disorder with an estimated incidence of 1 in 60,000. There are currently no FDA-approved medications for the treatment of mucous membrane pemphigoid, ...
What is the current status of trial NCT05263505?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2022-02-21. Estimated completion is 2023-09-11.
What interventions are being tested in trial NCT05263505?
The interventions under investigation include: Methotrexate (DRUG), Azathioprine (DRUG), Mycophenolate (DRUG), Baricitinib 2 MG [Olumiant] (DRUG).
Who is sponsoring clinical trial NCT05263505?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.